Moderna, Inc. (NASDAQ:MRNA) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 10:00 AM ET Company Participants Stephen Hoge - President Conference Call Participants Evan Wang - Guggenheim Securities Evan Wang [Call Starts Abruptly] Inaugural Health Innovation Conference. I'm Evan Wang, one of the senior biotech analysts at Guggenheim. I'm joined by Stephen Hoge, who is Moderna's President, Head of R&D and now Head of Commercial. I appreciate you being here, Stephen. I'm glad you've a ...

ToplineStocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, tumbling after reports surfaced that President-elect Donald Trump would select vaccine skeptic Robert F. Kennedy Jr. as the head of the Department of Health and Human Services.Trump announced his pick Thursday afternoon. (Photo by Tom Brenner for The Washington Post via Getty ... [+] Images)The Washington Post via Getty Images Key FactsTrump confirmed his selection of RFK Jr. on Thur ...

Moderna, Inc. (NASDAQ:MRNA) UBS Global Healthcare Conference November 13, 2024 6:30 PM ET Company Participants Jamey Mock - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Eliana Merle Good afternoon, everyone. Thank you for joining us at the UBS Healthcare Conference. I'm Eliana Merle. I'm one of the biotech analysts here at UBS. Very happy to have Moderna here with us today for fireside chat. Joining us from Moderna is Jamey Mock, Chief Financial Officer. Jamey, thank you so much f ...

On Thursday, Moderna Inc. MRNA reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion.The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.BofA Securities notes that Moderna’s stock rose early Thursday but ended the day lower, likely due to slowing vaccine trends and uncertainty around the company’s respiratory vaccine lineup, as well as new concerns related to Trump and Kennedy’s positions on vacci ...

Moderna (MRNA) reported $1.86 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 1.7%. EPS of $0.03 for the same period compares to -$1.39 a year ago.The reported revenue represents a surprise of +47.73% over the Zacks Consensus Estimate of $1.26 billion. With the consensus EPS estimate being -$1.89, the EPS surprise was +101.59%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-3467528 (State or Other Jurisdicti ...

Moderna, Inc. (MRNA) reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a loss of $1.89 per share. In the year-ago period, management incurred a loss of $9.53 per share.Revenues in the quarter were $1.86 billion, ahead of the Zacks Consensus Estimate of $1.26 billion. Total revenues rose nearly 2% year over year, driven by higher product sales.Moderna’s shares were up nearly 8% in pre-market trading today, likely due to the better-than-expected earnings rep ...

Key TakeawaysModerna shares rose Thursday morning after reporting better results than expected for the third quarter.The vaccine maker reported a surprise profit and higher revenue than expected.CEO Stéphane Bancel said the company is ahead of schedule on its plan to cut R&D costs by $1.1 billion over the next three years. Moderna (MRNA) reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs. Moderna ...

Call Start: 08:00 January 1, 0000 9:00 AM ET Moderna Inc. (NASDAQ:MRNA) Q3 2024 Earnings Conference Call November 7, 2024 8:00 am ET Company Participants Stéphane Bancel - Chief Executive Officer Stephen Hoge - President Jamey Mock - Chief Financial Officer Lavina Talukdar - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs Eli Merle - UBS Gena Wang - Barclays Michael Yee - Jefferies Tyler Van Buren - TD Cowen Terence Flynn - Morgan Stanley Evan Wang - ...

The other long-expected big news item for market participants this week comes this afternoon, with the Federal Open Market Committee (FOMC) determining a new Fed funds rate. This follows the “red wave” election on Tuesday that still shows stock market indexes going higher after a gangbusters market Wednesday. Both the Dow and the Nasdaq are +80 points at this hour, with the S&P 500 up +15 points.New Jobless Claims Stay Tame; Longer-Term Claims HigherThis being Thursday morning, we nearly always look for Wee ...